Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) EPS (Weighted Average and Diluted) (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of EPS (Weighted Average and Diluted) data on record, last reported at -$2.18 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) fell 581.25% year-over-year to -$2.18; the TTM value through Sep 2025 reached -$9.04, up 91.71%, while the annual FY2024 figure was -$23.51, 76.09% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$2.18 in Q3 2025 per BTAI's latest filing, up from -$2.45 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.32 in Q3 2024 and bottomed at -$92.93 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$8.63, with a median of -$1.84 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 4641.33% in 2023, then soared 96.87% in 2024.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.96 in 2022, then tumbled by 4641.33% to -$92.93 in 2023, then skyrocketed by 96.87% to -$2.91 in 2024, then increased by 25.09% to -$2.18 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$2.18 in Q3 2025, -$2.45 in Q2 2025, and -$1.5 in Q1 2025.